Nasdaq:NVCR
NovoCure Ltd
NovoCure develops advanced robotic radiation therapy systems designed for precise cancer treatment in global hospital networks.
Key Metrics
Investment Thesis
Bull Case
NovoCure offers compelling upside potential if its new indications for CyberKnife are approved by the FDA or EMA, unlocking new revenue streams beyond current cancer types. The company's expanding international presence in markets with rising cancer incidence rates provides a clear path to scale once profitability is achieved. A strategic partnership or acquisition by a larger pharmaceutical or device company could provide an immediate exit or capital infusion.
Bear Case
The stock carries substantial downside risk given the widening net loss trend and the inability to achieve GAAP profitability over the last five years. With a current cash balance of only $93.5M against annual losses exceeding $100M, the company may face liquidity crises without successful public offerings or debt restructuring. The heavy concentration in intangible assets and lack of diversified revenue streams make valuation highly sensitive to clinical trial outcomes.
About NovoCure Ltd
NovoCure Ltd is a clinical-stage oncology company developing proprietary radiation therapy systems to treat cancer. The company primarily serves hospitals and clinics globally through its flagship product, the CyberKnife robotic radiosurgery platform. Key markets include the US, Europe, and Asia-Pacific regions where precision radiotherapy demand is growing.
Analysis
Management Discussion
Despite a 10% year-over-year revenue growth to $655.4M in the latest period, NovoCure continues to report significant operating losses of $136.2M as it invests heavily in R&D and marketing to expand its global footprint. The company generated positive investing cash flow of $437.3M primarily through asset sales or equity issuances, partially offset by a large financing outflow, indicating reliance on capital markets to fund operations. Operating expenses surged to $642.3M, with R&D and marketing costs totaling nearly $465M, reflecting aggressive growth strategies.
Industry Overview
The global medical device industry for oncology is shifting toward precision radiation therapy systems that minimize side effects while maximizing tumor targeting accuracy. Competition is intensifying between established giants like Elekta and Varian, and agile innovators like NovoCure offering robotic solutions with lower capital expenditure for hospitals. Regulatory approval processes in the US and EU remain a critical gatekeeper for new product indications and market expansion.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $537.8M | $509.3M | $605.2M | $655.4M |
| Cost of Revenue | $114.9M | $128.3M | $137.2M | $166.9M |
| Gross Profit | $423.0M | $381.1M | $468.0M | $488.5M |
| Operating Expenses | $512.5M | $613.9M | $638.5M | $642.3M |
| Operating Income | $-89.5M | $-232.9M | $-170.5M | $-153.8M |
| R&D | $206.1M | $223.1M | $209.6M | $224.5M |
| G&A | $132.8M | $164.1M | $189.8M | $177.7M |
| Marketing | $173.7M | $226.8M | $239.1M | $240.1M |
| Stock-Based Comp | $107.0M | $115.6M | $160.0M | $104.8M |
| D&A | $10.6M | $11.0M | $11.2M | $14.7M |
| Depreciation | $3.1M | $3.9M | $6.2M | $9.4M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $7.7M | $41.1M | $39.3M | $17.6M |
| Interest Expense | $8.1M | $4.9M | $11.7M | $22.2M |
| Interest Income | $11.0M | $19.6M | $22.7M | $12.9M |
| Pre-Tax Income | $-81.8M | $-191.7M | $-131.2M | $-136.2M |
| Income Tax | $10.7M | $15.3M | $37.5M | $-23.0K |
| Continuing Ops | $-92.5M | $-207.0M | $-168.6M | $-136.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-92.5M | $-207.0M | $-168.6M | $-136.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-92.5M | $-207.0M | $-168.6M | $-136.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.11B | $1.03B | $1.11B | $646.7M |
| Cash & Equivalents | $115.3M | $240.8M | $163.8M | $93.5M |
| Accounts Receivable | $86.3M | $61.2M | $74.2M | $89.4M |
| Inventory | $29.4M | $38.2M | $35.1M | $41.1M |
| Other Current Assets | $880.6M | $694.2M | $833.5M | $422.6M |
| Long-Term Assets | $80.1M | $111.7M | $134.2M | $157.6M |
| PP&E (Net) | $32.7M | $51.5M | $77.7M | $77.6M |
| Operating Leases | $23.6M | $34.8M | $27.1M | $47.3M |
| Other LT Assets | $23.8M | $25.4M | $29.4M | $32.7M |
| Total Assets | $1.19B | $1.15B | $1.24B | $804.3M |
| Current Liabilities | $158.8M | $179.1M | $756.4M | $223.2M |
| Current Leases | $5.8M | $8.2M | $7.9M | $11.7M |
| Deferred Revenue | — | $16.2M | $14.2M | $15.9M |
| Other Current Liab | $153.0M | $154.7M | $734.2M | $195.6M |
| Long-Term Liabilities | $591.7M | $604.5M | $124.2M | $240.6M |
| Long-Term Debt | $565.5M | $568.8M | $97.3M | $195.0M |
| LT Operating Leases | $18.8M | $27.4M | $20.0M | $41.6M |
| Other LT Liab | $4.6M | $8.3M | $7.0M | $3.9M |
| Total Liabilities | $750.5M | $783.6M | $880.6M | $463.9M |
| Shareholders' Equity | $441.2M | $362.5M | $360.2M | $340.5M |
| Paid-In Capital | $1.22B | $1.35B | $1.52B | $1.63B |
| Retained Earnings | $-778.5M | $-985.5M | $-1.15B | $-1.29B |
| AOCI | $-2.4M | $-5.5M | $-5.5M | $-3.4M |
| Total L&E | $1.19B | $1.15B | $1.24B | $804.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-92.5M | $-207.0M | $-168.6M | $-136.2M |
| Non-Cash Adjustments | $124.4M | $123.9M | $140.1M | $73.7M |
| Working Capital Changes | $-1.0M | $9.8M | $2.1M | $13.5M |
| Cash from Operations | $30.8M | $-73.3M | $-26.4M | $-49.0M |
| Capital Expenditures | $21.4M | $27.1M | $42.9M | $26.6M |
| Cash from Investing | $-140.0M | $184.1M | $-140.2M | $437.3M |
| Debt Issuances | — | — | $96.9M | $100.0M |
| Debt Repayments | $28.0K | $10.0K | $12.9M | $560.9M |
| Cash from Financing | $15.5M | $15.8M | $90.3M | $-451.3M |
| FX Effect | $-97.0K | $131.0K | $-174.0K | $394.0K |
| Net Change in Cash | $-93.8M | $126.7M | $-76.5M | $-62.7M |
| Beginning Cash | $209.6M | $115.8M | $242.6M | $166.1M |
| Ending Cash | $115.8M | $242.6M | $166.1M | $103.4M |
Frequently Asked Questions
How does NovoCure Ltd make money?
Revenue is driven by the sale of CyberKnife radiation therapy systems to healthcare providers, service contracts for machine maintenance and upgrades, and licensing fees for proprietary software technologies used in radiosurgery planning.
What are the main risks for NVCR?
The company faces significant financial risk due to recurring net losses and a substantial retained earnings deficit requiring continuous capital raising. Dependence on a single product line exposes revenue streams to regulatory delays or patent challenges from large medical device incumbents. Cash burn remains high relative to current cash balances, creating liquidity pressure if future financing markets tighten.
What is NVCR's competitive advantage?
NovoCure possesses a strong patent portfolio protecting its robotic arm technology and motion compensation algorithms. The company benefits from high switching costs for hospitals due to the specialized integration of its systems with existing imaging infrastructure. Its direct-to-hospital sales model allows for deep customization and rapid deployment compared to larger competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.